Jeremy Graff
Allarity Therapeutics
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jeremy Graff as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:33 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05571969 · Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid TumorsAllarity Therapeutics · terminated · Advanced Solid Tumors · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:33 UTC. The ranking covers the 200 most relevant of 65 PubMed records, and a shared surname and initials can bring in a namesake. All 65 on PubMed
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.N Engl J Med · 20181,042 citationsRCR 38.8
- Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.Gastroenterology · 2001402 citationsRCR 11.3
- 304 citationsRCR 8.8
- Apalutamide and Overall Survival in Prostate Cancer.Eur Urol · 2021222 citationsRCR 12.6
- A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer.Invest New Drugs · 2015167 citationsRCR 6.3
- LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.Invest New Drugs · 2013135 citationsRCR 3.7
- Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.J Clin Pharmacol · 2007122 citationsRCR 3.6
- A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.J Immunother Cancer · 2020109 citationsRCR 4.1
- Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.Ann Oncol · 2019108 citationsRCR 3.9
- 107 citationsRCR 3.5